Date lodged: 28 September 2016
To ask the Scottish Government whether it will provide an update on the availability of pre-exposure prophylaxis.
Answered by: Aileen Campbell 5 October 2016
Truvada, the medicine used for HIV pre-exposure prophylaxis, or 'PrEP', has been granted a marketing authorisation by the European Commission for its use in the European Union. The next step is for the manufacturer Gilead Sciences International, to make a submission to the Scottish Medicines Consortium on the clinical and cost-effectiveness of Truvada for the purposes of PrEP. SMC will then consider whether the medicine can be accepted for use by the NHS in Scotland.
The Scottish Government's Chief Pharmaceutical Officer wrote to the manufacturer on 15 September 2016 asking them to make a submission quickly, and at a fair price, so that the SMC who can then consider it for routine use in NHS Scotland.